Latham Advises on US$120 Million Freeline Therapeutics Series C Investment

London team represents lead investor in biotechnology company’s fundraising round.

June 30, 2020

Latham & Watkins advised Novo Holdings A/S (Novo) as the lead investor in its Series C investment into Freeline Therapeutics, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases.

The Series C financing, raising US$120 million, was co-led by Novo, Eventide Asset Management and Wellington Management Company, with additional participation from Cowen Healthcare Investments, Acorn Bioventures and Ample Plus Fund.  

Latham’s team was led by London corporate partner Robbie McLaren, with associates Emily Cridland and Georgina Scott.  


Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.